PE20211294A1 - Anticuerpo que se une a vegf y a il-1beta y metodos de utilizacion - Google Patents
Anticuerpo que se une a vegf y a il-1beta y metodos de utilizacionInfo
- Publication number
- PE20211294A1 PE20211294A1 PE2021000884A PE2021000884A PE20211294A1 PE 20211294 A1 PE20211294 A1 PE 20211294A1 PE 2021000884 A PE2021000884 A PE 2021000884A PE 2021000884 A PE2021000884 A PE 2021000884A PE 20211294 A1 PE20211294 A1 PE 20211294A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- sequence
- amino acids
- 1beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UN ANTICUERPO QUE SE UNE A VEGF HUMANO Y A IL-1BETA HUMANA QUE COMPRENDE UN PARATOPO PARA VEGF Y UN PARATOPO PARA IL-1BETA DENTRO DE UNA PAREJA AFIN DE UN DOMINIO VARIABLE DE LA CADENA LIGERA (VL) Y UN DOMINIO VARIABLE DE LA CADENA PESADA (VH), EN DONDE EL DOMINIO VH COMPRENDE A) CDR-H1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID N° 13, B) CDR-H2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID N° 14 Y C) CDR-H3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID N° 15, Y EL DOMINIO VL COMPRENDE D) CDR-L1 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID N° 16, E) CDR-L2 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID N° 17 Y F) CDR-L3 QUE COMPRENDE LA SECUENCIA DE AMINOACIDOS DE SEC ID N° 8. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES VASCULARES OCULARES.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215023 | 2018-12-21 | ||
| PCT/EP2019/086529 WO2020127873A1 (en) | 2018-12-21 | 2019-12-20 | Antibody that binds to vegf and il-1beta and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211294A1 true PE20211294A1 (es) | 2021-07-20 |
Family
ID=64870356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000884A PE20211294A1 (es) | 2018-12-21 | 2019-12-20 | Anticuerpo que se une a vegf y a il-1beta y metodos de utilizacion |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11130804B2 (es) |
| EP (1) | EP3898671A1 (es) |
| JP (4) | JP7114813B2 (es) |
| KR (2) | KR20240042566A (es) |
| CN (6) | CN119708246A (es) |
| AR (1) | AR117468A1 (es) |
| AU (1) | AU2019406712B2 (es) |
| BR (1) | BR112021012022A2 (es) |
| CL (1) | CL2021001616A1 (es) |
| CO (1) | CO2021008755A2 (es) |
| CR (1) | CR20210332A (es) |
| IL (1) | IL283566A (es) |
| MX (1) | MX2021007421A (es) |
| MY (1) | MY199149A (es) |
| PE (1) | PE20211294A1 (es) |
| PH (1) | PH12021551470A1 (es) |
| SG (1) | SG11202106198YA (es) |
| TW (2) | TW202515909A (es) |
| UA (1) | UA129264C2 (es) |
| WO (1) | WO2020127873A1 (es) |
| ZA (1) | ZA202103643B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230061458A (ko) * | 2020-09-04 | 2023-05-08 | 에프. 호프만-라 로슈 아게 | Vegf-a 및 ang2에 결합하는 항체 및 사용 방법 |
| WO2024053224A1 (ja) | 2022-09-07 | 2024-03-14 | 住友電気工業株式会社 | 光学特性測定システム及び光学特性測定方法 |
| WO2025099120A1 (en) | 2023-11-09 | 2025-05-15 | F. Hoffmann-La Roche Ag | Multispecific antibodies with conditional activity |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US830930A (en) | 1905-11-22 | 1906-09-11 | E & T Fairbanks & Co | Weighing-scale. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| ID27960A (id) | 1998-07-23 | 2001-05-03 | Avebe B A | Komposisi perekat |
| EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
| CA2481656A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells in which activity of the protein involved in transportation of gdp-fucose is reduced or lost |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| WO2003085119A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| DK2289936T3 (en) | 2002-12-16 | 2017-07-31 | Genentech Inc | IMMUNGLOBULIN VARIATIONS AND APPLICATIONS THEREOF |
| EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
| NZ582315A (en) | 2003-01-22 | 2011-01-28 | Glycart Biotechnology Ag | Fusion constructs and use of same to produce antibodies with increased Fc receptor binding affinity and effector function |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PL1737891T3 (pl) | 2004-04-13 | 2013-08-30 | Hoffmann La Roche | Przeciwciała przeciw selektynie p |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| NZ553500A (en) | 2004-09-23 | 2009-11-27 | Genentech Inc Genentech Inc | Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| RU2488597C2 (ru) | 2005-02-07 | 2013-07-27 | Гликарт Биотехнологи Аг | Антигенсвязывающие молекулы, которые связывают egfr, кодирующие их векторы и их применение |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
| US9000130B2 (en) | 2010-06-08 | 2015-04-07 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| KR101614195B1 (ko) | 2011-03-29 | 2016-04-20 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| EP2726510B1 (en) | 2011-05-27 | 2023-03-08 | F. Hoffmann-La Roche AG | Dual targeting |
| CN104125852B9 (zh) | 2012-02-15 | 2017-05-17 | 弗·哈夫曼-拉罗切有限公司 | 基于Fc‑受体的亲和色谱 |
| SMT202100621T1 (it) | 2012-07-13 | 2022-01-10 | Roche Glycart Ag | Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari |
| BR112015013020A2 (pt) * | 2012-12-05 | 2017-07-11 | Dutalys Gmbh | método de geração de anticorpos biespecíficos, coleção de anticorpos ou seus fragmentos funcionais, de sequências de ácidos nucleicos, de vetores e de células hospedeiras, método de produção da coleção de anticorpos e de identificação de um anticorpo, anticorpo ou fragmento funcional e anticorpo biespecífico |
| HK1213578A1 (zh) | 2013-04-29 | 2016-07-08 | 豪夫迈‧罗氏有限公司 | 结合人fcrn的修饰的抗体和使用方法 |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| JP6744292B2 (ja) | 2014-07-29 | 2020-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| MX2017003123A (es) | 2014-09-12 | 2017-05-12 | Genentech Inc | Anticuerpos y conjugados modificados geneticamente con cisteina. |
| WO2016075034A1 (en) | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | ANTI-IL-1beta ANTIBODIES AND METHODS OF USE |
| WO2016075037A1 (en) * | 2014-11-10 | 2016-05-19 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use in ophthalmology |
| WO2017079768A1 (en) * | 2015-11-08 | 2017-05-11 | Genentech, Inc. | Methods of screening for multispecific antibodies |
| EP3519820B1 (en) * | 2016-09-30 | 2020-12-09 | H. Hoffnabb-La Roche Ag | Spr-based dual-binding assay for the functional analysis of multispecific molecules |
| WO2018210898A1 (en) * | 2017-05-18 | 2018-11-22 | F. Hoffmann-La Roche Ag | Reduction of application-related side reaction of a therapeutic antibody |
-
2019
- 2019-12-20 KR KR1020247009946A patent/KR20240042566A/ko not_active Ceased
- 2019-12-20 EP EP19836489.5A patent/EP3898671A1/en active Pending
- 2019-12-20 CN CN202411953327.0A patent/CN119708246A/zh active Pending
- 2019-12-20 TW TW113131340A patent/TW202515909A/zh unknown
- 2019-12-20 CN CN201980084480.5A patent/CN113195531B/zh active Active
- 2019-12-20 UA UAA202104073A patent/UA129264C2/uk unknown
- 2019-12-20 MX MX2021007421A patent/MX2021007421A/es unknown
- 2019-12-20 JP JP2021535578A patent/JP7114813B2/ja active Active
- 2019-12-20 CR CR20210332A patent/CR20210332A/es unknown
- 2019-12-20 MY MYPI2021003408A patent/MY199149A/en unknown
- 2019-12-20 CN CN202411953337.4A patent/CN119751690A/zh active Pending
- 2019-12-20 CN CN202411953347.8A patent/CN119708249A/zh active Pending
- 2019-12-20 BR BR112021012022A patent/BR112021012022A2/pt unknown
- 2019-12-20 PE PE2021000884A patent/PE20211294A1/es unknown
- 2019-12-20 AR ARP190103792A patent/AR117468A1/es unknown
- 2019-12-20 CN CN202411953333.6A patent/CN119708247A/zh active Pending
- 2019-12-20 PH PH1/2021/551470A patent/PH12021551470A1/en unknown
- 2019-12-20 AU AU2019406712A patent/AU2019406712B2/en active Active
- 2019-12-20 SG SG11202106198YA patent/SG11202106198YA/en unknown
- 2019-12-20 WO PCT/EP2019/086529 patent/WO2020127873A1/en not_active Ceased
- 2019-12-20 TW TW108146845A patent/TWI853867B/zh active
- 2019-12-20 KR KR1020217020190A patent/KR102652720B1/ko active Active
- 2019-12-20 CN CN202411953344.4A patent/CN119708248A/zh active Pending
- 2019-12-20 US US16/722,317 patent/US11130804B2/en active Active
-
2021
- 2021-05-27 ZA ZA2021/03643A patent/ZA202103643B/en unknown
- 2021-05-30 IL IL283566A patent/IL283566A/en unknown
- 2021-06-17 CL CL2021001616A patent/CL2021001616A1/es unknown
- 2021-07-01 CO CONC2021/0008755A patent/CO2021008755A2/es unknown
- 2021-09-08 US US17/469,044 patent/US11866490B2/en active Active
-
2022
- 2022-07-27 JP JP2022119854A patent/JP7342212B2/ja active Active
-
2023
- 2023-08-30 JP JP2023139510A patent/JP7680504B2/ja active Active
- 2023-11-15 US US18/510,174 patent/US20240101657A1/en active Pending
-
2025
- 2025-05-08 JP JP2025078193A patent/JP2025121995A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190212A1 (es) | Anticuerpos anti_ige | |
| PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
| PE20080214A1 (es) | Moleculas de anticuerpo que se unen a la il-17 humana | |
| PE20141186A1 (es) | Proteinas de union al tnf-alfa | |
| PE20191102A1 (es) | Anticuerpos anti-pd-1 y sus usos | |
| PE20221511A1 (es) | Anticuerpos anti-ly6g6d y metodos de uso | |
| AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
| PE20191131A1 (es) | Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| PE20230844A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos | |
| AR075925A1 (es) | Anticuerpos anti-alfa5beta1 (alfa5beta1: glicoproteina integrina) y sus usos | |
| AR080501A1 (es) | Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1) | |
| PE20120211A1 (es) | Anticuerpos que tienen especificidad por ox40 humana | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
| PE20140848A1 (es) | Anticuerpos monoclonales contra la proteina rgma y sus usos | |
| PE20211294A1 (es) | Anticuerpo que se une a vegf y a il-1beta y metodos de utilizacion | |
| AR080243A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
| AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
| PE20220279A1 (es) | Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos | |
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| AR115192A1 (es) | Anticuerpos | |
| PE20121645A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| PE20220487A1 (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos |